Biolase Inc.

1.11-0.0400-3.48%Vol 86.12K1Y Perf 17.35%
Nov 29th, 2023 15:59 DELAYED
BID1.10 ASK1.14
Open1.20 Previous Close1.15
Pre-Market- After-Market1.11
 - -  - -%
Target Price
14.00 
Analyst Rating
Strong Buy 1.00
Potential %
1.16K 
Finscreener Ranking
★★★+     51.38
Insiders Trans % 3/6/12 mo.
-/-/33 
Value Ranking
★★     45.52
Insiders Value % 3/6/12 mo.
-/-/85 
Growth Ranking
+     32.12
Insiders Shares Cnt. % 3/6/12 mo.
-/-/81 
Income Ranking
 —    -
Price Range Ratio 52W %
0.04 
Earnings Rating
Buy
Market Cap2.55M 
Earnings Date
9th Nov 2023
Alpha-0.08 Standard Deviation0.34
Beta1.34 

Today's Price Range

1.101.20

52W Range

1.07104.00

5 Year PE Ratio Range

-1.10-1.20

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-9.02%
1 Month
-34.71%
3 Months
-74.77%
6 Months
1 221.43%
1 Year
17.35%
3 Years
268.89%
5 Years
-3.48%
10 Years
-87.53%

TickerPriceChg.Chg.%
BIOL1.11-0.0400-3.48
AAPL189.37-1.0300-0.54
GOOG136.40-2.2200-1.60
MSFT378.85-3.8500-1.01
XOM102.34-1.5600-1.50
WFC43.780.41000.95
JNJ152.110.48000.32
FB196.640.99000.51
GE118.860.01000.01
JPM154.320.78000.51
Financial StrengthValueIndustryS&P 500US Markets
1.10
2.50
0.51
1.07
-12.40
Leverage Ratio 2.60
ProfitabilityValueIndustryS&P 500US Markets
36.80
-47.40
-46.30
-49.30
-54.56
RevenueValueIndustryS&P 500US Markets
34.41M
4.46
-5.14
-8.50
Earnings HistoryEstimateReportedSurprise %
Q01 2024--8.93-
Q01 2023--0.18-
Q03 2022--1.10-
Q02 2022--0.91-
Q01 2022--0.81-
Q04 2021-0.75-0.750.00
Q03 2021-0.75-0.5033.33
Q02 2021-1.00-0.5050.00
Earnings Per EndEstimateRevision %Trend
9/2019 QR-0.210.00-
3/2022 QR-0.0370.00Positive
12/2022 FY-0.10--
12/2022 FY-0.100.00-
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume86.12K
Shares Outstanding2.30K
Shares Float2.30M
Trades Count518
Dollar Volume97.18K
Avg. Volume273.89K
Avg. Weekly Volume58.96K
Avg. Monthly Volume456.09K
Avg. Quarterly Volume306.62K

Biolase Inc. (NASDAQ: BIOL) stock closed at 1.11 per share at the end of the most recent trading day (a -3.48% change compared to the prior day closing price) with a volume of 86.12K shares and market capitalization of 2.55M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 157 people. Biolase Inc. CEO is John R. Beaver.

The one-year performance of Biolase Inc. stock is 17.35%, while year-to-date (YTD) performance is 70.77%. BIOL stock has a five-year performance of -3.48%. Its 52-week range is between 1.07 and 104, which gives BIOL stock a 52-week price range ratio of 0.04%

Biolase Inc. currently has a PE ratio of -0.20, a price-to-book (PB) ratio of 0.37, a price-to-sale (PS) ratio of 0.16, a price to cashflow ratio of -, a PEG ratio of -0.18, a ROA of -52.51%, a ROC of -62.31% and a ROE of -122.83%. The company’s profit margin is -54.56%, its EBITDA margin is -46.30%, and its revenue ttm is $34.41 Million , which makes it $4.46 revenue per share.

Of the last four earnings reports from Biolase Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Biolase Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Biolase Inc. is Strong Buy (1), with a target price of $14, which is +1 161.26% compared to the current price. The earnings rating for Biolase Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Biolase Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Biolase Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 34.66, ATR14 : 0.13, CCI20 : -75.91, Chaikin Money Flow : -0.64, MACD : -0.18, Money Flow Index : 3.99, ROC : -22.03, RSI : 26.49, STOCH (14,3) : 10.39, STOCH RSI : 0.00, UO : 40.51, Williams %R : -89.61), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Biolase Inc. in the last 12-months were: Jonathan T. Lord (Sold 3 537 shares of value $2 653 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (100.00 %)
2 (100.00 %)
2 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Biolase Inc.

Biolase Inc is a US-based medical device company. It develops, manufactures, markets and sells laser systems in dentistry and medicine. The company also markets, sells and distributes dental imaging equipment, including cone beam digital x-rays and CAD/CAM intraoral scanners. It offers two categories of laser system products i.e. Waterlase (all-tissue) systems and Diode (soft-tissue) systems which allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a broad range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The majority of the company's revenue comes from the United States.

CEO: John R. Beaver

Telephone: +1 949 361-1200

Address: 4 Cromwell, Irvine 92618, CA, US

Number of employees: 157

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

55%45%

Bearish Bullish

58%42%

Bearish Bullish

59%41%

 

News

Stocktwits